Richard Williams has worked at the Kennedy Institute of Rheumatology since 1989 and was a Senior Lecturer (2007-2011) and then Reader (2011-2012) at Imperial College London before joining the University of Oxford.
He is also a Visiting Lecturer at Queen Mary University of London and the London School of Hygiene and Tropical Medicine and was recently appointed as an Editor of Frontiers in Immunology.
He has established an internationally recognised reputation in translational research and his early studies were instrumental in the development of TNF blocking biologics.
He has carried out numerous projects with British and overseas industrial partners, including Merck, Pfizer, GSK, UCB, Schering, Celgene and J&J and has led an MRC DPFS project on rheumatoid arthritis.
Ogbechi J. et al, (2020), Experimental Gerontology, 131, 110820 - 110820
Tseng W-Y. et al, (2019), Proc Natl Acad Sci U S A
cIAP1/2 inhibition synergizes with TNF inhibition in autoimmunity by down-regulating IL-17A and inducing Treg cells
WILLIAMS R. et al, (2019), Science Advances
INFERIORITY OF LABORAS OVER INCAPACITANCE TESTING TO MEASURE SPONTANEOUS MURINE OSTEOARTHRITIS PAIN
von Loga IS. et al, (2019), OSTEOARTHRITIS AND CARTILAGE, 27, S420 - S420
Aungier S. et al, (2019), Ann Rheum Dis